| Document Date: 2015-03-29 22:30:34
Open Document File Size: 17,35 KBShare Result on Facebook
City Tokyo / Milan / / Company Chugai Pharmaceutical Co. Ltd. / Taisho Pharmaceutical Co. Ltd. / Translation Taisho Pharmaceutical Co. Ltd. / Taisho Toyama Pharmaceutical Co. Ltd. / F. Hoffmann-La Roche Ltd. / / Country Japan / United States / Italy / / Event FDA Phase / / IndustryTerm osteoporosis treatment / healthcare professionals / prevention of osteoporosis / treatment of osteoporosis / / MedicalCondition Osteoarthritis / osteoporosis / Musculoskeletal Diseases / / Organization World Congress / Ministry of Health / International Osteoporosis Foundation / / Person Akira Ohira / Osamu Nagayama / Shigeru Uehara / / Position President / Head Office / Chairman & CEO / / Product Boniva / ibandronate / Bonviva® IV Injection / /
SocialTag |
Translation Taisho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate Oral Formulation, Bisphosphonate Antiresorptive Agent,